











A new villain in neuronal death





Excitotoxicity is the process by which the excitatory amino acid neurotransmitter, glutamate, causes neuronal toxicity (1). A landmark study in 1987 revealed that Ca2+ ion influx into neurons via glutamate N-methyl-D-aspartate receptor channels (NMDARs) could trigger excitotoxicity (2), making Ca2+ ions potential villains as well as functionally critical signaling molecules in neurons. On page XXX of this issue, Yan et al. (3) reveal a newly discovered mechanism of NMDAR-mediated excitotoxicity: a physical interaction with TRPM4, a transient receptor potential channel (4). Small molecule 'interface inhibitors' prevent NMDAR-TRPM4 physical coupling and eliminate excitotoxicity, in vitro and in vivo. This mechanism of excitotoxicity does not require NMDAR-mediated Ca2+ influx: TRPM4 is the new villain. Consequently, excitotoxicity can be halted without disrupting physiologically crucial NMDAR-mediated Ca2+ signaling. This presents opportunities in therapeutic design for disorders involving excitotoxicity, including stroke, epilepsy and neurodegeneration.
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Glutamate, released at excitatory synapses in the vertebrate brain, binds to NMDARs to induce Ca2+-dependent forms of synaptic plasticity (5) and survival-promoting intracellular signaling pathways involving cyclic AMP-responsive element-binding protein (CREB) (6). Glutamate can also spill over beyond the synapse and activate neighboring synaptic and extrasynaptic NMDARs. Excessive NMDAR-mediated Ca2+ influx is a widely accepted explanation for excitotoxicity (7,8). 
A hitherto separate class of ion channels, named TRPM4, are activated by cytoplasmic Ca2+ and are permeable to monovalent cations, Na+ and K+ (but not to Ca2+), mediating membrane depolarization (9). They have previously been linked to neuronal death: in mice, inhibiting TRPM4 channels reduces neurodegeneration and genetic deletion of Trpm4 protects against glutamate excitotoxicity (10). 
Yan et al. demonstrate a physical interaction between NMDARs and TRPM4 in hippocampal cell cultures and brain tissue from mice. NMDARs are typically composed of GluN1, GluN2 and sometimes GluN3 subunits (11). TRPM4 specifically interacts with GluN2A and GluN2B, but not GluN2C/D, GluN1 or GluN3. The site of NMDAR-TRPM4 interaction is narrowed down to a cytoplasmic region of TRPM4, which the authors name TwinF. The authors further identify a highly conserved isoleucine-rich cytoplasmic sequence in GluN2A and GluN2B to which TwinF binds; they name this I4. 
A TwinF peptide used to block NMDAR-TRPM4 interaction is neuroprotective in three assays of cell death: NMDAR-evoked excitotoxicity of neuronal cultures; oxygen-glucose-deprivation evoked cell death in neuronal cultures; and a small but significant reduction in ischemic brain damage in vivo following occlusion of the middle cerebral artery (MCAO) in mice. Small molecules that target the precise NMDAR-TRPM4 interaction, called compounds 8 and 19, were identified. In the mouse MCAO model and in retinal degeneration induced by the NMDA (the selective NMDAR agonist for which the receptor was named), intra-peritoneal delivery of compound 8 offers neuroprotection - a small but significant reduction in infarct volume and cell loss, as well as up to a 38% reduction in NMDAR-TRPM4 interaction. Thus, these small and simple molecules could potentially be delivered systemically to patients. Rapidly delivery would be required in acute excitotoxic injury, for example following stroke or epilepsy, while in chronic neurodegenerative diseases, possible contributions of excitotoxicity to disease progression (8) might be mitigated over a longer time course.
The authors hypothesize that NMDAR-TRPM4 coupling triggers ‘CREB shut off’ (CREB de-phosphorylation) (6, 12). TwinF and compounds 8 and 19 appear to ‘detoxify’ NMDAR signaling by preventing CREB shut off. In addition, TwinF reduces NMDAR-induced mitochondrial membrane dysfunction. By disrupting NMDAR-TRPM4 coupling, harmful signaling pathways are silenced while neuroprotective signaling pathways are spared (Fig 1). 
The mechanism by which physical coupling of NMDAR-TRPM4 brings about such neuroprotective effects is not yet elucidated, but it does not appear to involve Ca2+ ion signaling. A surprising finding is that blocking the NMDAR-TRPM4 interaction with TwinF or small molecule inhibitors has no effect on normal synaptic NMDAR channel function recorded in hippocampal CA1 pyramidal neurons in mouse brain slices. Nor is there any effect on NMDAR-mediated Ca2+ influx and signaling in vitro. TRPM4 channel activity is also unaffected by blocking NMDAR interaction. Conventional NMDAR antagonists typically impair cognitive function (13), most likely by blocking NMDAR-mediated synaptic transmission, Ca2+ influx and plasticity (5). Being able to target excitotoxicity, whilst having no detrimental effect on NMDAR ionic current flux or calcium permeability in vitro, is an important step. It remains to be confirmed that the small molecule inhibitors have no detrimental effects in vivo.
A physical coupling between TRPM4 and NMDARs in mediating excitotoxicity explains a conundrum in NMDAR research: why NMDARs located at synapses appear to mediate pro-survival signaling, whilst NMDARs located away from the synapse appear to prevent this and indeed trigger pro-death signaling pathways (6,8,12,14). Previous explanations for this include the sub-cellular localization of different signaling molecules or different concentrations of Ca2+ ion influx at synaptic versus extrasynaptic sites. As TRPM4 is absent from synapses, this suggests that NMDAR-TRPM4 complexes would only form extrasynaptically, offering a satisfying explanation to this puzzle. 
Considerable research effort has focused on the role of Ca2+ in NMDAR-mediated excitotoxicity. The study of Yan et al. introduces a new villain, TRPM4. This requires re-evaluation of the role of NMDARs in neuronal death. It may lead us to redirect our research efforts away from Ca2+ ions and towards physical interactions of NMDARs and it could provide another argument against developing NMDAR antagonist and channel blocker therapies. It is unknown if the NMDAR-TRPM4 interaction will prove to be the primary (or even exclusive) excitotoxicity mechanism in a broader range of neurons. For example, neurodegeneration in Huntington’s and Parkinson’s diseases affects the basal ganglia (12), whereas Yan et al. studied hippocampal neurons. There is evidence for acute and chronic excitotoxicity in human neurological disorders (8) and so it may be insightful to screen post-mortem human brains from patients with neurodegenerative diseases for NMDAR-TRPM4 interactions. If higher amounts of interaction are seen compared with healthy subjects, can small molecule interaction inhibitors be designed to produce a sufficiently robust yet safe disruption? Another intriguing thought is whether NMDAR-TRPM4 interaction is triggered under normal physiological conditions and plays an important functional role – or is it purely a pathological response to injury? After more than 30 years of research, will calcium signaling be shown to have little importance in excitotoxicity: is it, after all, a hero and not a villain in neuronal signaling?
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Disrupting glutamate receptor interactions favors neuroprotection over excitotoxicity.
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